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The Current Status 
of Liver Transplantation 
THOMAS E. STARZL UniiJersity of Colorado 
More than thirty patients have now undergone liver transplantation in Denver, some 
more than once, and survivals of up to two and a half years have been achieved. 
Through this and other experience it has been learned that graft viability is more critical 
than histocompatibility matching but that the most important factor in th~ ultimate 
outcome is prevention of rejection through vigorous immunosuppressive therapy. 
Treatment of terminal liver disease by transplantation 
was founded on the encouragement and knowledge pro-
vided by the steadily. improving experience in renal trans-
plantation. The liver, however, is a far more complicated 
organ, and its derangement leads to vastly more complex 
physiologic impairments. Liver patients are further handi-
capped, as are heart patients, by the lack so far of a satis-
factory means of artificial support comparable to renal 
dialysis that could take 'over the organ's compromised 
functions during the wait for a suitable donor, or during 
the critical immediate postoperative period~ Live donors, 
of course, are not feasible, timing is of the essence, and 
the circumstances for obtaining an optimal homograft are 
rarely if ever ideal. The transplanted liver must function 
efficiently practically from the moment of anastomosis or 
the patient is lost. 
Despite these and other formidable difficulties, the past 
10 years have furnished enough progress in the laboratory 
and clinic to let us state that liver transplantation is now 
a feasible and legitimate, albeit imperfect, form of treat-
ment, one that may in certain cases be considered as a last 
best hope. Human survivals for up to two and one half 
years have been achieved. A great .deal has been and is 
being learned - at a pace suggesting that the next phase, 
when liver transplants will have at least as much a chance 
as kidney grafts now have, is not far off. Eventually much 
more than that will need to be accomplished, of course, 
but rather than engage in speculation it would appear 
more useful here to record how far we have come and to 
identify the major hurdles immediately ahead. 
When research in liver transplantation was in its early 
stages, it was hoped that as the liver played a significant 
role in graft rejections, hepatic homografts might enjoy 
a better fate than other transplants because presumably 
the grafted liver would not participate in rejecting itself. 
The case for this rather mystical view seemed even 
strengthened by certain experiences with laboratory ani-
mals. When immunosuppression in canine recipients was 
stopped after four months a surprising number of animals 
continued to thrive, with no signs of rejection or with 
rejection episodes that waxed or waned remittently. One 
such dog is still alive, with stable liver function seven years 
after the transplant. This phenomenon of "graft accep-
tance" had been noted in dogs with renal transplants, but 
less frequently. 
If the liver thus seemed to be an immunologically more 
favored organ in dogs, its status' in pigs - as observed by 
Garnier in Paris, Terblanche in Bristol, Calne in Cam-
bridge, and in our own laboratory -'- was .even more note-
worthy. In some experiments with pigs not treated with 
immunosuppressive agents, identifiable homograft rejec-
tion did not occur. In other experiments, rejection was 
indolent and spontaneously reversed. This state of affairs 
applied only to a min~rity of animals. Nevertheless, these 
results had to be attributed to some special privilege of 
the liver, since porcine skin and kidney grafts were regu-
larly rejected in the usual way. 
These observations in both dogs and pigs (and now 
in other animals) invited certain hypotheses in addition 
to the one stated above that the new liver helped create 
an internal milieu favorable to itself. There were the pos-
sibilities that the liver was inherently less antigenic than 
other organs, that its relatively great antigenic mass was 
a beneficial factor, that its enormous regenerative capacity 
made it less susceptible than other tissues to the effects 
of chronic rejection, or (CaIne) that it possessed or re-
leased some special factor promoting the induction of 
specific immunologic tolerance. 
Whatever the explanation, overstatement of the case 
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for the liver's privileged status could 
lead to erroneous conclusions about 
the practical requirements for im-
munosuppressive therapy following 
hepatic transplantation in man. At a 
research level, another danger could 
stem from .the notion that hepatic 
transplantation, especially in the pig, 
is somehow qualitatively unique. The 
fallacy of such a contention is obvious 
from the fact that even in the "easy" 
pig model the majority of untreated 
liver recipients die from acute rejec-
tion. In dogs and humans, control of 
hepatic rejection may be difficult or 
impossible in spite of very heavy im-
munosuppressive therapy. 
It is my opinion that liver homo-
grafts differ from other organs only 
in the degree of host immunologic 
response they evoke in all species, in-
cluding the pig. In this context, two 
key observations first made with kid-
neys have been extended to the liver, 
and there is little doubt that they 
apply to other tissues as well. The 
first is the reversibility of rejection, 
w'hich has been well documented in 
: 
canine, porcine, and human recipients 
of hepatic homografts. In patients, 
reversal usually requires intensifica-
tion of treatment, but it has sometimes 
been noted without any change in the 
preexisting therapy, suggesting that 
such recoveries had an element of 
spontaneity. As mentioned earlier, 
"spontaneous remission" of rejection 
in the absence of all therapy has oc-
curred both in dogs and pigs, particu-
larly the latter. The reactions of the 
liver in all three species are undoubt-
edly expressions of the same phe-
nomenon, differing only quantita-
tively. 
The second observation of overrid-
ing practical and theoretical interest 
concerns what has already been re-
ferred to as "graft acceptance." In 
. many of the human kidney recipients 
~ treated almost a decade ago, it was 
shown that a melting away of host 
resistance to the homograft occurred 
surprisingly early after transplanta-
tion, often following an acute rejec-
tion crisis. This was manifested by 
eventual declines in the doses of im-
Suprahepatic Vena Caval Anastomosis 
)} I 
Gastroduodenal Artery 
Insertion of second homograft in child pictured opposite proceeded as shown above, 
with cholecystoduodenostomy performed for biliary drainage and the donor celiac axis. 
attached to the reCipient proper hepatic artery. Note that a cuff of the {irst homograft's 
inferior vena cava was left to lengthen the suprahepatic connection. 
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munosuppressive agents necessary to 
retain stable graft function. In many 
patients, the level of chronic immuno-
suppression has proved to be less than 
that which at the outset failed to pre-
vent the onset of a severe rejection. 
It is probable that all treatment 
could be stopped in some of these 
human renal recipients whom we have· 
now followed for seven or eight years, 
but we have not dared to take such 
a drastic step. However, as described 
earlier, therapy has been successfully 
discontinued in dogs after kidney 
transplantation and even more con-
sistently after liver replacement, indi-
cating that graft acceptance may 
become complete. In pigs, the bar-
rier of natural host resistance is 
apparently low enough so that the 
cycle of hepatic graft acceptance can 
be completed without any immuno-
suppression at all. Viewed in this way, 
the curious pig liver experiments be-
come only a special example of, rather 
than an exception to, a general prin-
ciple of transplantation. Recently, 
Perper hllS provided evidence to sup-
port both this concept and the original 
idea that there is a slight but limited 
biologic advantage in transplanting 
the liver rather than the kidney. Per-
per showed that a three-day course of 
heterologous antilymphocyte globulin 
(A L G) treatment (or other short-term 
therapeutic maneuvers) in pigs per-
mitted long-term acceptance of kid-
neys in precisely the same way as it 
does with the liver in the absence of 
all iatrogenic intervention. 
It is indisputable that some element 
of acceptance of various kinds of 
grafts occurs often in humans under 
the appropriate conditions of immuno-
suppression and that the degree to 
which this develops is a prime deter-
minant of the long-term prognosis. 
Unfortunately, the reason for the 
change in the host-graft relationship 
is not known. More than one immuno-
logic pathway may be involved. 
Schwartz and Talmage first called at-
tention to the possibility that the 
continuous presence of a transplanted 
organ in a host being treated with im-
munosuppressive therapy could lead 
to a selective loss of responsiveness to 
antigens. The suggestion here is th~t 
specific lymphocyte clones, induced to 
replicate by the graft antigens, are 
thereby rendered more vulnerable to 
the killing effect of immunosuppres-
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,ive agents than is the rest of the lym-
tlhocyte population. Inasmuch as the 
llaintenance of such activated cell 
iines appears to be thymus-dependent 
~ven in adult life, at least in some ex-
perimental animals, it is reasonable to 
be curious about the effect of thymec-
tomy as an adjuvant immunosuppres-
sive measure. The results of thymec-
tomy in a series of our human renal 
transplants were inconclusive; though 
those with thymic excision did not 
have better survival or superior renal 
function, there were fewer and less 
severe histopathologic abnormalities 
when the grafts were examined long 
after transplantation. 
At any rate, the concept of specific, 
differential tolerance through "clone 
stripping" can partly explain the char-
acteristic cycle of rejection and re-
versal that occurs after whole organ 
transplantation both in treated ani-
mals and man and in the weak, self-
resolving crises in the untreated pig. 
Moreover, this concept is consistent 
with the fact that a wide variety of 
agents that are capable of general 
immunologic crippling can also pro-
vide specificity of action under the 
stipulated conditions of immuno-
suppressive treatment during pres-
ence of the antigen. 
To date, few investigations to 
establish the presence or absence of 
classic immunologic tolerance to 
donor tissue have been carried out in 
human recipients of chronically func-
tioning renal homografts. It would be 
interesting to know if skin from these 
donors would be accepted. One of the 
reasons why such a test has not been 
carried out in patients is the potential 
A reiecting Iwmograft in a two-year-old 
child treated by transplantation for extra-
hepatic biliary atresia is shown at top at 
the time of its removal, 68 days folloWing 
insertion. (The liver weighed 250 gm at 
insertion, 880 at removal.) The child re-
ceived a second homograft (lower photo); 
his subsequent course was extremely com-
plicated, in part because of the large size 
of the second liver (which came from a 
seven-year-old donor), which severely 
crowded the abdominal caVity. Fortunate-
ly, swelling due to reiection was delayed 
for a month and eventually the child was 
able to eat a full diet. Although iaundiced, 
the child lived for one year after the sec-
ond transplant and died of hepatic failure. 
(For gross appearance of first graft on 
pathologic examination see next page.) 
Cross subcortical infarcts were easily seen in the reiected homograft removed from the 
patient described on pages 48-49. Some of the necrotic areas revealed by sliCing appeared 
to have been devitalized very recently, others seemed to be older, and both types tended 
. to be near the surface. The maior blood vessels were found free of clots. 
risk of precipitating an immune re-
action that could damage the kidney. 
Of course, the liver recipient's viable 
donor tissue is not available for such 
an experiment even if this were a 
desirable undertaking. 
Fritz Bach has provided evidence 
that at least some kidney recipients 
develop true tolerance to their donors. 
Dr. Bach performed mixed lympho-
cyte cultures with peripheral blood 
from a number of our renal recipients 
and their donors two to four years 
after transplantation. He was able'to 
demonstrate in some cases that re- -
cipient lymphocytes no longer de-
veloped blast transformation when 
exposed to killed donor white cells, 
although they reacted vigorously to 
third-party cells. It is important to 
note that this was not always the case 
and that animal experiments with skin 
transplants similarly showed mixed 
results. 
These ambivalent findings do not 
disprove tolerance through clone strip-
ping so much as they suggest that at 
least another mechanism of graft ac-
ceptance is involved. One such mecha-
nism, termed enhancement, has been 
envisioned as a process in which im-
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munoglobulins synthesized by the 
activated lymphoid tissues return to 
the target tissue and coat it or protect 
it in some way that is not yet under-
stood. Antigraft antibodies, selectively 
capable of being absorbed by the 
nucleated cells of the original donor, 
have been detected in patients carry-
ing well-tolerated renal transplants. 
Extensive immunoglobulin deposition 
has been demonstrated by immuno-
fluorescence techniques in. long-
functioning kidney homografts, but 
this finding usually has an adverse 
connotation rather than a favorable 
one. 
An understanding of the means by 
which grafts are accepted may hold 
the key to improvements in therapy. 
When we come to know more about 
these mechanisms it may prove possi-
ble to arrange the conditions required 
for graft acceptance in advance of the 
arrival of the homograft rather than 
to rely on their development while 
fighting. the battle of rejection. The 
result might well be the prevention of 
rejection with far less immunosup-
pressive crippling of the immune ap-
paratus in the critical postoperative 
period. In this connection it is hearten-
ing to refer to the experiments of 
Stuart and his colleagues at the Uni-
versity of Chicago. When enhancing 
antibodies were combined with toler-
ance induction by donor-specific anti-
gen pretreatment, rat renal trans-
plants functioned 18 months and 
longer, even in the presence of strong 
histocompatibility barriers, the ab-
sence of immunosuppression, and the 
retention of immunologic reactivity to 
most antigens. 
Another way to improve clinical re-
sults might be by effective donor-reci-
pient matching of histocompatibility 
(H L-A) antigens. Unfortunately, the 
state of our knowledge about human 
histocompatibility systems is still 
primitive. While a good match be-
tween siblings appears to provide a 
more favorable prognosis after renal 
transplantation than a poor match, our 
experience with unrelated subjects 
provides no such correlation and has 
led us for the moment to the possibly 
heretical practice of ignoring the ques-
tion of H L-A matching altogether in 
cadaveric cases. In liver transplanta-
tion, in which nonrelated cadaveric 
sources must be utilized exclusively, 
we have had some excellent results 
with poor histocompatibility matches 
and some discouraging results despite 
close matches. Not only has a correla-
tion with tissue typing been absent 
with regard to clinical outcome but 
K. A. Porter of London has found no 
connection between the quality of the 
match and the appearance of the 
hepatic homograft at subsequent his-
tologic examination. Until the dis-
crimination of the matching methods 
is improved in nonrelated cases, we see 
no justification for denying a patient 
an available organ solely on the basis 
of poor serologic histocompatibility. 
Nor do we even use most favorable 
matching as an instrument of selec-
tion among candidates for transplan-
tation. At the present time, a more 
valid criterion may be: Who has the 
most pressing need? 
None of this should be construed as 
denigrating the ultimate value of his-
tocompatibility determination in the 
transplantation of the future. What is 
at issue today is acceptance of the fact 
that typing between nonrelated indi-
viduals with serologic methods is im-
precise, incomplete, and incapable of 
consistently predicting the extent of 
the antigenic confrontation in individ-
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ual cases or the effectiveness with 
which immunosuppression may be 
used. The mixed lymphocyte culture 
method of Hirschhorn and Bach may 
be more discriminating and its find-
ings more relevant for the selection of 
recipients. However, the procedure 
takes the better part of a week to per-
form, much too long for practical ap-
plication in most cadaveric cases at 
the present time. 
Here we turn to the question of 
logistiCs, for the problem of obtaining 
a fresh, functioning, nonischem~c 
liver is paramount and provides the 
strongest correlation with success or 
failure. A major advance in one tech· 
nical aspect of logistics, that of organ 
preservation and banking, would not 
only reduce the present inevitable 
waste of cadaveric organs but would 
also make more feasible the use of 
tissue typing when these techniques 
become more predictive. Selection on 
the basis of favorable histocompatibil-
ity would then become far more real-
istic and meaningful. 
In the meanwhile, the most favor-
able prognostic thing that can be done 
for the hepatic transplantation candi-
date is to assure him an undamaged 
liver. 
In discussing homograft quality, 
the technical details of organ preser-
vation become interwoven with, or 
even distinctly secondary to, ethical 
considerations about the conditions 
for the pronouncement of donor death 
and problems of cooperation by the 
medical and lay community. Unques-
tionably, one of the most important 
advances in transplantation has been 
social in nature - acceptance by the 
public of the concept of cadaveric or-
gan removal. In turn, this was made 
possible by a willingness of many in 
the medical profession to identify po-
tential donors, approach family mem-
bers at the time of their bereavement, 
or indicate in other ways their belief 
in the propriety of these efforts. The 
consequence has been a major contri-
bution to our transplantation program 
by a well-informed community. 
I believe that the transplantation 
team's style of community relations is 
a vital factor in determining the suc-
cess of a cadaveric program. The diffi-
cult decisions required by the several 
parties to organ replacement cannot 
be made objectively in the atmosphere 
of a fishbowl. I have the impression 
that securing donors is less of a prob-
lem where transplant teams deliber-
ately keep the matter in its proper 
perspective as a private concern be-
tween doctor and patient. The general 
public, quite naturally, is keenly inter-
ested in the drama and medical 
achievement represented by trans-
plantation, and it is likewise impor-
tant to transplantation that the public 
be informed of legitimate progress. 
This can and has been done in many 
areas impersonally, with restraint, 
without exaggeration, and without 
infringing on the personal right to 
privacy of the individuals involved. 
After the donor has been identified 
and made available, an effort is made 
to maintain good liver perfusion up to 
the last possible moment in order to 
minimize the ischemic damage that 
even a short unperfused period may 
wreak under normothermic condi-
tions. The extraordinary efforts re-
quired to prevent circulatory depres-
sion in the donor in the face of a hope-
less prognosis usually reqlJire expla-
nation to relatives and represent a 
problem of emotional substance to all 
parties. 
Ultimately, a final decision to dis-
continue supportive measures must be 
made after all is in readiness to pro-
ceed with the recipient. During the 
first years of liver transplantation at 
the University of Colorado a consider-
able physiologic penalty was accepted 
because of criteria that insisted on 
both brain death and cessation of 
heartbeat before organ removal. The 
price of this insistence was the loss of 
critical time and the occurrence of 
An untreated canine hepatic homograft is shown six days after 
transplantation (left). Portal veins (clear spaces) and central vein 
(arrow) are surrounded by dense cellular infiltration and there iK~ 
centrilobular necrosis with hemorrhage (hematoxylin and eosin 
stain, x30). Photo at right shows normal licer architecture in an-
other canine homograft one year after transplantation. This dog 
received azathioprine for fO(U months, no additional therapy. It 
is still alive after some seven years. 
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ischemic damage during both the 
agonal stages of circulatory failure 
and in the minutes after cardiac ar-
rest. The reason for accepting these 
conditions was the fear that the qual-
ity of terminal care for the donor 
might be compromised by the pro-
nouncement of death while there was 
still a heartbeat. 
In 1968 we liberalized our criteria 
in accordance with the concept of ir-
reversible brain injury as it was first 
outlined and applied at the University 
of Louvain, Belgium, by Alexandre 
and later defended by the Harvard ad 
hoc committee. Our experience since 
then has convinced us that anxieties 
about terminal care were unfounded. 
Acceptance of the brain death concept 
alleviated one of the most serious 
problems in liver transplantation, for 
it virtually eliminated the interval of 
normothermic ischemic injury and 
permitted the organ to be taken in the 
presence of an intact and effective 
circulation. 
The subsequent preservation of the 
liver is also of vital importance and 
at our center we use one or more pres-
ervation modalities, depending on 
circumstances and always including 
organ hypothermia. With the accept-
ance of brain death as a criterion, it 
is often possible to maintain a natur-
J1ly perfused liver in situ practically 
up to the moment of its excision. After 
removal, the liver may be quick-
cooled by running a chilled electrolyte 
solution through the portal vein, thus 
lowering its temperature to about 10° 
or 15° C, which is sufficient for ade-
quate preservation during the hour or 
so required for the vascular anasto-
moses in the recipient. Should the 
donor's heart stop before the recipient 
is ready, it is possible to employ the 
procedure used before 1968 (when 
cardiac arrest was required); by means 
of a heart-lung machine, circulation 
in the cadaver is reinstituted in com-
bination with cooling. When longer 
The location of the orthotopiC liver homo-
graft. between the bowel and the heart, 
helps explain the predisposition of these 
patients to graft sepsis and eventual gan-
grene. As the drawing opposite suggests, 
invading microorganisms (purple dots) 
may enter via portal vein or through the 
recnnstructed biliary tract; the lungs aLso 
an'lt high risk. 
: I~ ..., ~: 
periods of preservation and storage 
are needed (which has not been the 
case at this center since 1968) the 
liver may be removed and placed in a 
chamber such as that devised by 
Brettschneider, which combines per-
fusion, refrigeration, and hyperbaric 
oxygenation - this last process having 
an empiric favorable effect for reasons 
not clear. Conceivably, one could add 
to the perfusate a variety of metabolic 
inhibitors such as those reported by 
Webb, Fonkelsrud, and others. In one 
of our cases, the perfusion chamber 
permitted preservation of a liver with- . 
out undue damage for nine hours, 
long enough for the recipient to make 
a transcontinental flight to Denver 
and to be prepared for surgery. 
The above methods are still a far 
cry from the objectives of organ bank-
ing, and it must be conceded that 
there has been less progress in this 
than in any other aspect of transplan-
tation. The importance of effective 
organ storage over the long term is 
obvious not only for reasons already 
noted but also to make it possible by 
portable devices to bring suitable and 
available organs to patients on a na-
tional exchange basis. Fresh ideas 
about organ preservation, either with 
solid state or perfusion techniques, are 
badly needed, for existing protocols 
seem to have reached the limit of their 
effectiveness. The importance of this 
problem has been acknowledged by a 
one-day "think tank" recently spon-
sored in Bethesda by the NIH, the 
Veterans Administration, and the Na-
tional Research Council to smoke out 
some innovative ideas as well as to 
promote the funding with which to 
test these ideas. 
Now, let us consider a few inter-
esting aspects of the liver rephicement 
operation. This procedure was first 
attempted in dogs by Francis Moore 
of Boston, and independently in our 
laboratories a short time later. As 
might be expected, the transition from 
animal experimentation to clinical ap-
plication required some major techni-
cal adjustments and at least in one 
important and unexpected way dem-
onstrated the need to be alert to the 
special requirements of human physi-
ology. \Vith removal of the host liver 
it is necessary to cross-clamp tempo-
rarily the great veins draining the in-
testines and the lower half of the 
, , 
body. In dogs, if provision is not made 
for decompression of the distal venous 
pools during the anhepatic phase, the 
animals either die of shock on the 
operating table or expire at a later 
time because of irreparable damage to 
the.mesenteric vessels. It was as-
sumed that the same precaution would 
be necessary in humans and this was 
accomplished in the first five human 
recipients by plastic tube bypasses 
from splenic and/or femoral veins to 
the external jugulars. There was a 
dismaying incidence of pulmonary 
emboli that caused or contributed to 
the death of at least two of the recip-
ients. It was suspected that the clots 
either originated within the bypasses 
and were actually carried to the lungs 
during the operation or were formed 
a short time later at or near the site 
where the femoral catheter had been 
inserted. To our relief, the omission 
of the venous decompression proce-
du,re in later patients did not produce 
any serious or long-lasting circulatory 
effects, including hypotension. Al-
though a slight duskiness of the intes-
tine developed in some recipients, it 
immediately disappeared when blood 
flow was restored through the recon-
structed venous channels. One can 
explain the ease with which portal and 
vena caval cross-damping was toler-
ated by man's inherently richer net-
work of potential collateral channels 
for return of blood to the right heart. 
Presumably, also, the size and ramifi-
cations of these vessels are further in-
creased as a result of the disease in 
the liver. Venous decompression with 
bypasses has not been used in any re-
cent case. The ability to omit this step 
has been a major technical advantage. 
In planning a liver transplantation, 
the surgeon must be prepared for a 
high incidence of anatomic variations 
of either the graft or host structures. 
These have been noted in almost 40% 
of our cases. Multiple arteries have 
been the most frequent anomalies. 
\Vhen the recipient has had these, we 
have usually connected the graft ce-
liac axis to the host aorta. When the 
multiplicity has been of the transplant 
vessels, multiple arterial anastomoses 
or other variant procedures have been 
used. There is no question that the 
need to improvise in these situations 
imposes an extra risk, particularly in 
very young recipients whose arteries 
are quite small and thin-walled. In pa-
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~ __ --s-- Terminating' 
in Left 
Hepatic 
Artery 
Gastroduodenal Artery 
Multiple arteries, in either graft or host, often complicate opera-
tion. In both situations shown, two graft 'arteries were encoullt-
ered. Left: problem was solved by individually anastomosing the 
vessels to branches of recipient hepatic artery. Right: donor celiac 
axis was first ;oined to recipient common hepatic artery. After 
blood flow was restored through larger left branch, other (right) 
donor artery, which had Originated from superior mesenteric ar-
tery, was revascularized by being attached to donor splenic artery. 
: tients with biliary atresia, anomalies 
• may be so complex as to make it vir-
tually impossible to succeed. Two of 
our infants with biliary atresia had a 
curious type of malrotation in which 
the portal vein passed in front of the 
pancreas and duodenum, the arterial 
blood supply issuing from the supe-
rior mesenteric artery rather than 
from the celiac axis, which was ab-
sent as was the retrohepatic inferior 
vena cava. In both cases corrective 
maneuvers to overcome the structural 
deficits were unsuccessful and the pa-
tients died within a few days. 
The critical problem of obtaining 
adequate bile drainage and avoiding 
technical errors that may lead to leak-' 
age or obstruction may also be compli-
cated by biliary tract anomalies, and 
the surgeon must be prepared to tailor 
his procedures to the individual case. 
An end-to-end anastomosis of the 
common duct, if it were normal, 
would have the advantage of preserv-
ing the sphincter of Oddi, thus pro-
viding drainage through a normal dis-
tal channel and reducing the chances 
of reflux of food or bacteria. This 
method, which of course is not avail-
able in the case of biliary atresia, is 
considered the procedure of choice by 
some surgeons. However, from our ex-
perience this anastomosis involves too 
high a risk of leakage and infection. 
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We consider it undesirable to leave a 
T-tube prosthesis and a drain in an 
immunosuppressed patient when the 
duct reconstruction is in close prox-
imity to the portal venous and hepatic 
arterial anastomoses. Further, there 
may not always be an adequate blood 
supply to the distal portion of the 
homograft common duct, which nor-
mally receives its principal arterializa-
tion from retroduodenal sources but 
now must depend on retrograde flow 
from arteries in the central hepatic 
hilum. Therefore, when feasible, we 
use the safer if somewhat less elegant 
technique of anastomosing the gall-
bladder directly to the duodenum and 
ligating the common duct. 
Some dangers attend ligation of the 
transplant common duct if certain 
anomalies go unrecognized. Commu-
nication between the cystic and com-
mon ducts may not always be at the 
point of their apparent juncture. In 
one patient the ducts were externally 
fused but separated by an internal 
septum; in another, the homograft 
cystic duct passed behind the common 
duct and descended for almost two 
inches as one compartment of a 
double-barreled lumen. In both cases 
biliary drainage was inadvertently ob-
structed when the common duct liga-
ture closed both parallel passages, a 
technical error subsequent surgery 
failed to correct and that proved fatal. 
Some of the vascular and ductal 
anomalies could have been predicted, 
resulting either in better planning for 
surgery or in a decision not to operate 
at all. These earlier cases did not, 
however, have the benefit of the exten-
sive arteriography and cholangiog-
raphy that we now use routinely in 
the donor and sometimes in the recip-
ient as well. 
Other problems during and after 
operation may be caused by derange-
ments in the coagulation mechanism 
that may result either in hemorrhage 
or thrombosis. As one would expect, 
acute bleeding can be particularly 
troublesome during the actual liver 
transplantation. To begin with, the 
very nature of the underlying hepatic 
pathology produces a portal hyperten-
sion in nearly every patient and the 
mechanics of the operation tend to ex-
aggerate it. The usual consequence is 
mechanical bleeding that can rapidly 
assume nightmare proportions during 
the procedure. Many normal coagula-
tion factors that might help control 
this unpleasant situation are depend-
ent on the liver and are therefore de-
fective in the· diseased recipient. 
These coagulation factors may be 
even more deficient during the anhe-
patic phase, or they may subsequently 
.... 
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Phrenic Nerve 
Anomalies of communication b· "veen the cystic and common 
ducts must also be watched for during operation. In situation 
shown at left, the cystic and common ducts were erternaUy fused 
but separated by an internal septum. When cholecystoduodeno-
stomy and common duct ligation were carried out, the result was 
total biliary obstruction. At right, right phrenic nerne is inadver-
tently included in clamp occluding suprahepatic vena cava, as is 
a piece of the diaphragm. Temporary phrenic paralysis resulted. 
be of dubious quality, depending on 
the state of preservation of the homo-
graft - how much ischemia it has suf-
fered and how much immediate func-
tional capability it has retained. 
When hemorrhage occurs, the sur-
geon must use any and all available 
hemostatic tactics - ligating, sutur-
ing, cauterizing - until the revascu-
larized homograft can participate in 
what is hoped will be appropriate co-
agulation function. With our earlier 
patients, whose homografts were gen-
erally of less than optimal quality for 
the reasons previously stated, we at-
tempted to meet bleeding problems by 
administering thrombogenic agents. 
However, hypercoagulability was 
caused in some instances. The unac-
ceptable incidence of pulmonary em-
bolism in these patients led us to 
abandon this approach. 
In retrospect, it is possible that the 
coagulability induced by exogenous 
thrombogenic agents might be prohi-
bitively additive to the clotting 
brought by the homograft, which, 
when it begins to function, conceiv-
ably overreacts. Indeed, the better the 
condition of the transplant, the 
greater the risk of unwanted coagula-
tion. Almost every series of liver 
transplants, including our own, has at 
least one example of thrombosis of the 
hepatic arterial circulation to which 
. '. 
the rebound phenomenon may have 
contributed. The use of anticoagulants 
to forestall this emergency is danger-
ous. Proved intravascular clotting 
during the operation would be an in-
dication for heparin, but such proof 
is hard to come by. Moreover, hepa-
rinization is a double-edged maneu-
ver: depressed clotting can have de-
vastating effects on patients submitted 
to such major trauma and with so 
many potential bleeding sites. 
In general,we now believe that it is 
advisable to avoid the manipulation 
of the clotting process either with 
thrombogenic or anticoagulant agents. 
Instead, our current approach is to 
leave correction of coagulation abnor-
malities to natural processes, interven-
ing only under special circumstances 
and for very specific indications. 
During operation, there are other 
metabolic abnormalities than those 
concerned with coagulation. Perhaps 
anesthesia deserves a comment here; 
it, too, is a complex problem in liver 
transplantation. Not only is the proce-
dure long and difficult but, even more 
important, it is an operation on the 
very organ involved most in the me-
tabolism and detoxification of most 
common anesthetics. At any point 
during-the operation the liver is either 
inherently impaired, absent, or un-
tried in its new setting. Hence the task 
in anesthesia is to administer correctly 
drugs that, first, are not hepatotoxic 
and, second, do not depend primarily 
on the liver for their degradation. The 
anesthesia in most of our early cases 
was administered by J. Antonio Al-
drete. He has tended to rely mainly 
on such volatile agents as fluroxene 
added to a nitrous oxide-oxygen mix-
ture in nonexplosive concentrations 
below 4.4%. This combination per-
mits use of electrocautery, gives flex-
ibility in lightening or deepening an-
esthesia, and allows anesthesia to be 
abruptly stopped if the changing phy-
siologic circumstances require it. 
So much for some of the more im-
portant technical difficulties asso-
ciated with liver transplantation. 
There is, of course, a long list of other 
technical pitfalls: adrenal venous in-
farction, air embolism, crushing of the 
right phrenic nerve by too high a 
clamp on the upper vena caval cuff, 
to mention but a few. The reader in-
terested in a more detailed discussion 
of these and other surgical problems 
is referred to Experience in Hepatic 
Transplantation (see Selected Read-
ing on page 60). These technical 
matters have played a major role in 
the mortality encountered in our. first 
cases. However, as deaths from such 
causes are highly avoidable, surgical 
technique is of .Iess critical signifi-
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cance to the future of transplantation 
than are the immunologic problems, 
The most important factor in success-
ful transplantation remains the pre-
vention of graft rejection by the host. 
Immunosuppressive therapy in liver 
transplantation has borrowed heavily 
from the experience gained with hu-
man renal transplants. Two general 
treatment programs were evolved 
with the simpler kidney model and 
then applied to the liver recipients. 
The first protocol that was used from 
1962 to 1966 for all organ recipients 
at the University of Colorado con-
sisted of double-drug treatment with 
azathioprine and the synthetic adrenal 
cortical steroid, prednisone. Evolution 
of the use of these two agents to-
gether, appreciation of their marked 
synergism, and demonstration that 
rejection could be readily reversed by, 
increasing the steroid doses were' 
among the advances that made clin-
ical transplantation practical and in-
troduced what is known as the mod-
em era of this field. But in spite of 
\ moderately satisfactory results with 
renal transplantation, the double-drug 
therapy either did not prevent rejec-
tion of hepatic homografts or else 
proved too toxic to permit host sur-
vival. Six patients so treated in liver 
transplantation from 1963 to 1965 
died in a month or less. 
In 1966, heterologous antilympho-
cyte globulin (A L G) was introduced 
clinically at our center as a third im-
munosuppressive agent, added to the 
drugs mentioned above. Since then, 
this triple-drug therapy has been 
given to all our renal, hepatic, and 
cardiac recipients. In our experience, 
rejection has been more easily and. 
regularly controlled, and the risks and 
morbidity imposed by the necessity 
for high-dose steroid therapy have 
been reduced. It must be admitted 
that not all transplant surgeons con-
cede the need for A L G. However, 
those most familiar with its use have 
enthusiastically confirmed the value of 
the triple-drug regimen, beginning 
with Traejer of Lyon, France, and in-
cluding most recently Simmons and 
Najarian of Minneapolis. The latter 
authorities advocate raising the heter-
ologous serum 'with cultured lympho-
blasts as the antigen rather than ma-
ture lymphoid tissue and recommend 
administering the subsequently re-
fined A L G by the intravenous rather 
56 Hospital Practice March 1971 
E 
than the originally employed intra-
muscular route: All of our human liver 
recipients who achieved chronic sur-
vival were treated with the combina-
tion of azathioprine, prednisone, and 
intramuscular A LG. In the event of a 
rejection episode, it is the steroid com-
ponent that has proved most amen-
able to quick adjustment of dosage. 
\Ve will not review here the various 
hypotheses explaining the actions of 
these immunosuppressive drugs (see 
"Antilymphocytic Serum: Its Proper-
ties and Potential," HOSPITAL PRAC-
TICE, May 1969). But, as was stated 
_earlier, the method by which these 
agents are used in conjunction with 
the actual transplantation may permit 
selective abrogation of the host rejec-
tion response. Were this not true, 
there would be little hope of returning 
patients to life in an unrestricted en-
vironment since each of the individual 
agents can cause general immunologic 
crippling more or less in proportion 
to the dose used. The most obvious 
penalty of a depressed immune system 
is heightened susceptibility to infec-
tion. However, it has also become 
obvious that chronically immunosup-
pressed patients have an increased 
vulnerability to de novo malignancies. 
In our own series of chronic survivors 
after renal transplantation, more than 
5% have developed either mesenchy-
mal or epithelial malignant tumors. 
Almost all other major transplanta-
tion centers have recorded this com-
plication, which is presumably due to 
failure of the depressed immunologic 
surveillance mechanism to identify the 
tumor tissues as alien. 
In addition to the foregoing gen-
eral liabilities of immunosuppression, 
there are some special risks for the 
liver candidate. One is the fact that 
hepatic injury in all kinds of organ 
recipients has commonly been pro-
duced by the agents, individually or 
in combination, of the therapeutic 
regimen. In some instances, viral 
hepatitis, apparently made chronic by 
the partial immunologic invalidism of 
the host, has been a plausible explana-
tion; but in others, hepatotoxicity of 
the drugs was probably responsible. 
\"lith liver malfunction, dose control 
of some of the agents may become 
difficult since the liver participates in 
their pathways of action. These 
hepatic factors are obviously im-
portant in any situation requIrIng 
immunosuppression, but plainly they 
have heightened significance for a 
traumatized, transplanted liver fight-
ing for survival in a new and hostile 
environment. 
Though infection is a major risk to 
any immuno~uppressed patient, for 
the liver recipient postoperative sepsis 
of the graft itself has proved to be a 
special problem - partly because of 
the anatomic location of the ortho-
topically placed organ, interposed so 
to speak between the intestinal tract 
and the heart. Bacteria from the 
bowel, particularly of the gram-nega-
tive variety, can be brought into 
contact with the transplanted liver via 
intestinal veins draining into the 
portal vein, or, alternatively, by retro-
grade spread up the duct system after 
passage through the biliary anasto-
mosis. In either event, the presence of 
nonviable hepatic tissue provides a 
perfect medium for bacterial growth. 
Eventually, piecemeal gangrene of the 
transplant can result, with character-
istic nonvisualizing areas on the liver 
scans, gram-negative bacteremia, and 
all the findings of generalized sepsis. 
Early in our clinical series, the 
above fintlings of graft and systemic 
infection led us to consider the essen· 
tial problem to be that of bacterial in-
vasion and prompted us to reduce the 
immunosuppression. This decision 
was tragically incorrect and was fol-
lowed by necrosis and infection of 
large parenchymal areas. Experience 
soon taught us that ischemia of por-
tions of the liver was the initiating 
event, and that the basis for the 
ischemia was rejection. Consequently, 
immunosuppression should ordinarily 
be increased rather than reduced if 
this complication is thought to be im-
pending. When this was done by giv-
ing substantially higher doses of 
prednisone (as noted, the only highly 
dose-maneuverable component of the 
immunosuppressive triad), the in-
cidence of regional hepatic gangrene 
fell to zero. It should be added that 
our prophylactic treatment protocol 
includes heavy antibiotic treatment for 
the first postoperative week, including 
agents effective against gram-negative 
bacteria, after which this therapy is 
stopped. 
\Vith the ac(] i1isition of experience, 
other important issues have also been 
clarified, including that of the indica-
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An "indolent" type of rejection characterized the clinical course 
of the child who received two homografts (see page 49); this 
proved to be the type nwst difficult to treat. Rejection of the first 
transplant began on the 13th postoperative day and progressed 
slowly; horse ALe had to be stopped after 18 days because of 
severe local reaction. Jaundice then developed; other measures of 
liver function were maintained for many weeks despite the fact 
that the child was extremely ill. Desensitization was attempted 
in the hope of resuming horse ALe treatment but was eventually 
abandoned. Note hypergammaglobulinemia toward end of sec-
ond month. Onset of rejection after second transplant was delayed 
about a month; by this time rabbit ALe was available for treatment. 
tions for liver replacement. A brief 
summary of our first 33 consecutive 
recipients, treated from March 1963 
to 12 months ago, can be used to illus-
trate these indications. 
The 33 patients were aged 11 
months to 68 years. The indication 
for 12 of these transplants was hepa-
toma, and an additional unsuspected 
hepatoma was found in a four-year-old 
child treated for intrahepatic biliary 
atresia. The latter is the only one of 
this group still alive; now 12 months 
after the operation she shows no evi-
dence of recurrence of neoplasia. As 
for the other hepatoma patients, seven 
died within 39 days. Badly damaged 
homografts were a major cause of 
failure in five who were among our 
early patients in the period before the 
criterion of brain death was applied, 
while technical accidents, with sub-
phrenic abscesses and bile peritonitis, 
were the major causes of death in the 
other two. Of the five hepatoma pa-
tients who had more prolonged sur-
vival - 76, 143, 339, 400, and 432 
days-metastases developed in all, and 
in four instances the recurrences were 
directly responsible for death. Be-
cause of this high rate of recurrent 
carcinoma, it has become our policy 
to consider liver replacement for hepa-
toma only under the most exceptional 
circumstances, even though our ex-
perience and that of Caine have 
demonstrated the possibility of an 
occasional tumor cure. 
Far more desirable candidates are 
those without neoplasms even though 
the technical difficulties in benign 
hepatic disease are more severe be-
cause the patients tend to be sicker 
and to have more advanced portal 
hypertension. Moreover, if the diag-
nosis is biliary atresia, an increased 
incidence of vascular anomalies can be 
expected to compound the difficulties 
together with the small size of the 
structures to be anastomosed in these 
young patients. Nevertheless, the 
longest survivors of liver transplanta-
tion in the world are those who had 
this disor"r~rK Of our own series of 
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Orthotopic Liver Hornotransplantations In Denver 
Date at Donor 
Patient Opera. Suroival Age Age 
Number Disease I tion (dnys) (years) (years) Cause at Death· 
1 Extrahepatic biliary atresia 3-1-63 0 3 3 Hemorrhage 
2 Hepatoma, cirrhosis 5-5-63 22 4-8 55 Pulmonary emboli, sepsis 
3 Cholangiocarcinoma 6-24-63 7-1/2 68 69 Sepsis, pulmonary emboli, 
GI bleeding 
4- Hepatoma, cirrhosis 7-16-63 6-1/2 52 73 Pulmonary emboli, ? hepatic 
failure, pulmonary edema 
5 Hepatoma, cirrhosis 10-4--63 23 29 64 Sepsis, bile peritonitis, hepatic 
failure 
6 Hepatoma 11-9-66 7 29 73 Hepatic failure, sepsis 
7 Extrahepatic biliary atresia 5-21-67 10 11/12 1 Hepatic failure, sepsis 
8 Hepatoma 7-23-67 400 1-7/12 1-6/12 Carcinomatosis 
9 Extrahepatic biliary atresia 7-31-67 133 1-9/12 4 Septic hepatic infarction, 
hepatic failure 
10 Extrahepatic biliary atresia 9-5-67 186 1-1/12 1-6/12 Septic hepatic infarction, 
hepatic failure 
11 Extrahepatic biliary atresia 10-8-67 61 1-2/12 1-8/12 Septic hepatic infarction 
12 Extrahepatic biliary atresia 11-24--67 105 1-4/12 1-2/12 Septic hepatic infarction 
13 Extrahepatic biliary atresia 2-9-68 90lt 2 3 Peritonitis 
10 
14 Hepatoma 3-17-68 432t 16 27 Carcinomatosis, peritonitis 
17 
15 Hepatoma, cirrhosis 4-14-68 339 44- 20 Carcinomatosis 
16 Extrahepatic biliary atresia, 5-26-68 4071 1-11/12 3 Hepatic insufficiency 
; 7 
17 Hepatoma 6-18-68 35 24 22 Pneumonitis 
18 Extrahepatic biliary atresia 6-29-68 4 1 1-9/12 Hepatic artery thrombosis 
19 Extrahepatic biliary atresia 7-20-68 91511 4 10 (Alive) 
20 Posthepatitic cirrhosis 8-13-68 1/2 8 10 Nonthrombotic occlusion of 
and cholangiectasis hepatic artery 
21 Extrahepatic biliary atresia 8-20-68 1/2 2 5 Portal vein thrombosis 
22 Laennec's cirrhosis 10-24--68 10 33 25 Biliary duct obstruction, hepatic 
and renal failure 
23 Hepatoma 10-26-68 143 15 6 Carcinomatosis 
24 Extrahepatic biliary atresia 11-10-68 11 3 2 ? Hepatic arterial insufficiency, 
hepatic failure 
25 Hepatoma 2-11-69 39 45 20 -Bile peritonitis, sepsis, hepatic 
failure 
26 Intrahepatic biliary 5-11-69 76 11 17 GI hemorrhage, intraabdominal 
atresia, hepatoma sepsis, metastases left lung 
!7 Wilson's disease 7-15-69 56011 11 11 (Alive) 
:8 Laennec's cirrhosis 7-26-69 13 39 22 Bile peritonitis, disrupted 
choledochocholedochostomy 
9 Intrahepatic biliary atresia 9-20-69 378 5-1/2 10 Hepatic insufficiency, chronic 
/ aggressive hepatitis 
0 Extrahepa tic biliary atresia 9-24-69 37 11/12 2 Partial biliary obstruction, 
cholangitis, pneumonitis 
Juvenile cirrhosis 1-8-70 9 15 19 Massive homograft necrosis 
2 Laennec's cirrhosis 1-16-70 3 46 17 Unexplained coma 
3 Extrahepatic biliary 1-22-70 370 11 3-10/12 7-11/12 (Alive) 
atresia, hepatoma 
act.wlily. 71Iost of{ these patients had other potentiaUy kthal complicotions bcs1des those listed, The tenn "sepsis" is wed loosely 
ird 901 da"s after first transpumtation. 19 days after retransplantatiall 
",d 432 days after first transplantatiall . .52 days after retransplantation 
ied 407 days after first transplantation, 340 da.ys aftll1' retran.."lantation 
ive as of Jail. 26, 1971 
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15 patients with biliary atresia, 
treated a year or longer ago, including 
the child with the incidental hepatoma 
mentioned above, five lived longer 
than one year and two are still sur-
viving with completely normal liver 
function, one year and two and a half 
years, respectively, after operation. 
The three late deaths after IS, IS;{a, 
and 30 months were from recurrent 
hepatic insufficiency caused in two 
instances by chronic rejection and in 
the third probably by indolent viral 
hepatitis. Another four children sur-
vived 61 to 186 days, all expiring 
from regional hepatic gangrene for 
which the apparent cause was too 
little immunosuppression in the early 
posttransplantation period. The six 
other recipients with biliary atresia 
died within the firSt 40 days, two from 
hepatic n:!crosis probably attributable 
to ischemia of the donor organ, two 
from thrombosis of the hepatic artery 
or portal vein, one from a non-
thrombotic occlusioq of the hepatic 
artery, and the remaining one from 
generalized infection and, pneumonia. 
Six patients were treated for cir-
rhosis a year or longer ago, with the 
disappointing record of five early 
deaths. Reasons for the heavy acute 
mortality included the wretched phy-
sical condition of the recipients, major 
hemorrhage due to portal hyper-
tension and depressed coagulation, 
and technical or metabolic mishaps. 
The survivor is an ll-year-old child 
whose cirrhosis was secondary to Wil-
son's disease. After liver replacement 
the child suffered an extremely severe 
rejection crisis, but the process was 
eventually reversed, with normal liver 
function now continuing 18 months 
after the operation. Moreover, the new 
liver, which was biopsied at 6 and 17 
months, has not reaccumulated copper 
and it appears to .have corrected the 
genetic error in c~pper metabolism-
a finding that may be important in the 
search for the etiology of this disease. 
The course of an acute rejection is shown 
at right in record of a 23-year-old woman 
who underwent transplantation for hepa-
toma. Although the rejection crisis was 
overcome promptly, she died of pseudo-
monas pneumonia after 3S days. Even be-
fore the onset of iaundice he, course was 
markedly febrile and she had severe bleed-
ing problems: note marked depression of 
prothrombin time and fibrinogen concen-
tration on daylJ 10 through 13. 
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Scalls w,illg TC99 .1f were made in .i5-year-
old boy treated for hepatoma. Reiectioll 
begall about a week after operation, as 
swelli'lg on day 6 illdicates, and lasted 
about two weeks. By-day 68 allteroposteri-
or scali TetuTlied to about the same dimen-
siolls as had been present shortly aftcr the 
tramplOlltatioll, but the lateral view 
showed that the liver moss was ill creased. 
Liver fUliction at this time was completely 
normal. The pickup of the isotope re-
mailled homogeneous through the period 
of observation, except possibly at 31 days. 
The homograft was eventually destroyed 
by tumor recurrence alld the boy died 143 
dnys after the transplant operation. 
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Undoubtedly, one reason for the. 
bad experience with cirrhotic patients 
has been a reluctance to recommend 
such therapy except in the agonal 
stages of the disease. But now that the 
feasibility of long-term survival and 
rehabilitation has been demonstrated, 
transplantation at an earlier time 
probably sho.uld be considered, par-
ticularly in postnecrotic cirrhosis in' 
which the maximum value of medical 
management and of abstinence from 
alcohol has already been realized. 
With another of our patients-one 
not in the series described above-
there have been exceptionally interest-
ing circumstances of transplantation. 
A 28-year-old woman with chronic 
active hepatitis, she was operated on 
August 9, 1970. For at least two 
years before the operation, as well as 
on the day of the transplantation, im-
munodiffusion tests for the Australia 
antigen were positive. This gave us an 
opportunity to examine the thesis that 
this antigen has an essentially hepatic 
source. The argument for this propo-
sition was supported by the immediate 
disappearance of the antigen from the 
bloodstream after the operation. Al-
most two months later it reappeared; 
and within a few days there followed 
an attack of acute serum hepatitis 
with joint pain, anorexia, jaundice, 
and evidence of hepatic necrosis by 
transaminase determinations. Fortu-
nately, her liver function abnormali-
ties have regressed nearly completely, 
but she is still Australia antigen-posi-
tive, now five months posttransplanta-
tion. It remains to be seen whether 
the virus will doom the new liver to 
the same fate as the old one, whether 
the long·term pace of the infection 
will be affected by the chronic im· 
munosuppression, and whether the· 
patient will continue to be a. virus 
carrier. The case has other interesting 
implications. It is customary to think 
of the incubation period of infoctious, 
diseases in terms 'Of the host immune 
defenses. In this patient, the immune 
apparatus was retained but system-
atically weakened. Yet, the latent 
period of the disease was about that 
to be expected with a fresh infection, 
indicating that the incubation period 
in this patient was primarily con· 
cerned with the-target organ. 
Thus far,' I have confined discus· 
sion strictly to the kind of operation 
(termed orthotopic transplantation) 
in which the diseased host liver is re-
moved and replaced. The alternative 
to this procedure in patients with 
benign disease is auxiliary hepatic 
transplantation, in which the native 
liver is not disturbed and the hepatic 
homograft is placed in some abn'Ormal 
location such as the paravertebral 
gutter, splenic fossa, or pelvis. Special 
technical and metabolic problems that 
have been encountered with· auxiliary 
transplantation cannot be reviewed 
here but they have been detailed in 
Experience in Hepatic Transplanta. 
tion. The results with the auxiliary' 
procedure in animals and in limited 
clinical trials have not been particu-
larly encouraging. 
In summary, orthotopic liver trans-
plantation has led to the prolongation 
of useful life. Among our first 33 
recipients, 9 lived a. year or longer, 
and their chances for survival rose 
with the increase in our experience. 
The longest survival to date exceeds 
2'h years. With more experience, 
with successful efforts to reduce the 
toxicity of immunosuppressive agents, 
with improvements in histocompati-
bility typing, and with advances in 
preservation and storage techniques, 
the record can be expected to improve. 
Even now, patients with nonmalig. 
nant terminal liver disease and with 
no other hope for recovery can be 
candidates forliver transplantation. 0 
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Starz\' TE with the assistance of Put· 
nam C\V: Experience in Hepatic 
Transplantation. WB Saunders Com· 
pany, 1969 
! 
t 
t 
1 
.. 
, 
'. 
. . 
f: 
l <. r 
t, 
